The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario
Abstract
Targeted therapy with ALK inhibitor crizotinib offers significant improvement in clinical outcome for treatment of EML4–ALK fusion positive non-small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of companion EML4-ALK genetic testing in combination with crizotinib treatment in the second-line setting for advanced NSCLC in Ontario. We performed a cost-effectiveness analysis using a Markov model from a Ministry of Health...
Paper Details
Title
The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario
Published Date
May 1, 2014
Journal
Volume
17
Issue
3
Pages
A90 - A90
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History